1. Cho YU. The role of next-generation sequencing in hematologic malignancies. Blood Res 2024;59:11.

2. Fernández Aceñero MJ, Díaz Del Arco C. Hereditary gastrointestinal tumor syndromes: when risk comes with your genes. Curr Issues Mol Biol 2024;46:6440–6471.

3. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005;23:276–292.

4. Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin 2011;61:327–359.

5. Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA 2017;318:825–835.

6. Hwang SM. Genomic testing for germline predisposition to hematologic malignancies. Blood Res 2024;59:12.

7. Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia--a review. Br J Haematol 2008;140:123–132.

8. Segel GB, Lichtman MA. Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells Mol Dis 2004;32:246–261.

9. Trottier AM, Cunningham L, Godley LA. Hereditary hematopoietic malignancies: considerations for optimizing diagnosis and management. Curr Oncol Rep 2025;27:1019–1030.

10. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200–1228.

11. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022;140:1345–1377.

12. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022;36:1703–1719.

13. Hendricks RM, Kim J, Haley JS, et al. Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts. Leukemia 2025;39:400–411.

14. Klco JM, Mullighan CG. Advances in germline predisposition to acute leukaemias and myeloid neoplasms. Nat Rev Cancer 2021;21:122–137.

15. Chlon TM, Patnaik MM. Germline DDX41 mutant predisposition syndromes: slow driver states to hematological malignancies. Am J Hematol 2023;98:1673–1676.

16. Badar T, Nanaa A, Foran JM, et al. Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms. Haematologica 2023;108:3033–3043.

17. Kusne Y, Badar T, Lasho T, et al. Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. Br J Haematol 2025;206:1109–1120.

18. Maierhofer A, Mehta N, Chisholm RA, et al. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing. Blood Adv 2023;7:7346–7357.

19. Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 2015;27:658–670.

20. Kida J, Chlon TM. Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding. Curr Opin Hematol 2025;32:67–76.

21. Parvatiyar K, Zhang Z, Teles RM, et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol 2012;13:1155–1161.

22. Stein SC, Falck-Pedersen E. Sensing adenovirus infection: activation of interferon regulatory factor 3 in RAW 264.7 cells. J Virol 2012;86:4527–4537.

23. Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu YJ. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol 2011;12:959–965.

24. Jiang Y, Zhu Y, Liu ZJ, Ouyang S. The emerging roles of the DDX41 protein in immunity and diseases. Protein Cell 2017;8:83–89.

25. Ma J, Ross SR. Multifunctional role of DEAD-box helicase 41 in innate immunity, hematopoiesis and disease. Front Immunol 2024;15:1451705.

26. Mosler T, Conte F, Longo GMC, et al. R-loop proximity proteomics identifies a role of DDX41 in transcription-associated genomic instability. Nat Commun 2021;12:7314.

27. Hwang WC, Park K, Park S, et al. Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation. Leukemia 2024;38:1353–1364.

28. Shinriki S, Hirayama M, Nagamachi A, et al. DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells. Leukemia 2022;36:2605–2620.

29. Weinreb JT, Ghazale N, Pradhan K, et al. Excessive R-loops trigger an inflammatory cascade leading to increased HSPC production. Dev Cell 2021;56:627–640e5.

30. Chlon TM, Stepanchick E, Hershberger CE, et al. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell 2021;28:1966–1981e6.

31. Kadono M, Kanai A, Nagamachi A, et al. Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia. Exp Hematol 2016;44:745–754e4.

32. Tungalag S, Shinriki S, Hirayama M, et al. Ribosome profiling analysis reveals the roles of DDX41 in translational regulation. Int J Hematol 2023;117:876–888.

33. Jiang Y, Zhu Y, Qiu W, et al. Structural and functional analyses of human DDX41 DEAD domain. Protein Cell 2017;8:72–76.

34. Wilkinson ME, Charenton C, Nagai K. RNA splicing by the spliceosome. Annu Rev Biochem 2020;89:359–388.

35. Ma J, Mahmud N, Bosland MC, Ross SR. DDX41 is needed for pre- and postnatal hematopoietic stem cell differentiation in mice. Stem Cell Reports 2022;17:879–893.

36. Singh RS, Vidhyasagar V, Yang S, et al. DDX41 is required for cGAS-STING activation against DNA virus infection. Cell Rep 2022;39:110856.

37. Lee KG, Kim SS, Kui L, et al. Bruton’s tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response. Cell Rep 2015;10:1055–1065.

38. García-Muse T, Aguilera A. R loops: from physiological to pathological roles. Cell 2019;179:604–618.

39. Weinreb JT, Gupta V, Sharvit E, Weil R, Bowman TV. DDX41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish. Haematologica 2022;107:644–654.

40. Stepanchick E, Wilson A, Sulentic AM, et al. DDX41 haploinsufficiency causes inefficient hematopoiesis under stress and cooperates with p53 mutations to cause hematologic malignancy. Leukemia 2024;38:1787–1798.

41. Makishima H, Saiki R, Nannya Y, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood 2023;141:534–549.

42. Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood 2022;140:756–768.

43. Li P, Brown S, Williams M, et al. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood 2022;140:716–755.

44. Choi EJ, Cho YU, Hur EH, et al. Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. Haematologica 2022;107:510–518.

45. Cheloor Kovilakam S, Gu M, Dunn WG, et al. Prevalence and significance of DDX41 gene variants in the general popula tion. Blood 2023;142:1185–1192.

46. Gurnari C, Makishima H, Durmaz A, et al. A dedicated system accounting for specific germline/somatic genomic constellations is essential to predict outcomes in DDX41-mutant myeloid neoplasia. Blood 2024;144(Supplement 1):1332.

47. Quesada AE, Routbort MJ, DiNardo CD, et al. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol 2019;94:757–766.

48. Korotev SC, Cheng JX, Haribabu Y, et al. Overall cancer risk in people with deleterious germline DDX41 variants. Haematologica 2025;110:2076–2090.

49. Sébert M, Passet M, Raimbault A, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood 2019;134:1441–1444.

50. PDQ Cancer Genetics Editorial Board. DDX41-associated myeloid malignancies (PDQ®) Health professional version. National Cancer Institute (NCI). PDQ Cancer Information Summaries. Bethesda (MD): NCI, 2002. 51. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–424.

52. Li P, White T, Xie W, et al. AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia 2022;36:664–674.

53. Baliakas P, Tesi B, Cammenga J, et al. How to manage patients with germline DDX41 variants: recommendations from the Nordic working group on germline predisposition for myeloid neoplasms. Hemasphere 2024;8:e145.

54. Goyal T, Tu ZJ, Wang Z, Cook JR. Clinical and pathologic spectrum of DDX41-mutated hematolymphoid neoplasms. Am J Clin Pathol 2021;156:829–838.

55. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid 2022;1:EVIDoa2200008..

56. Döhner H, DiNardo CD, Appelbaum FR, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 2024;144:2169–2173.

57. Lachowiez CA, Ravikumar VI, Othman J, et al. Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML. Blood 2024;144:2788–2792.

58. Sébert M, Freiman L, Chaffaut C, et al. Clinical impact of ge netic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 2024;38:918–922.

59. Toumeh N, Jabban Y, Nanaa A, et al. Clinical outcome and molecular profile in patients with DDX41 mutation hot-spots. Hematol Rep 2025;17:26.

60. Bataller A, Loghavi S, Gerstein Y, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 2023;98:1780–1790.

61. Tiong IS, Stevenson WS, Wall M, et al. Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide. EJHaem 2023;4:1212–1215.

62. Nannya Y, Tobiasson M, Sato S, et al. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood Adv 2023;7:3624–3636.

63. Cedena MT, Rapado I, Santos-Lozano A, et al. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget 2017;8:106948–106961.

64. Nanaa A, He R, Foran JM, et al. Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients. Br J Haematol 2024;204:171–176.

65. Negoro E, Radivoyevitch T, Polprasert C, et al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia 2016;30:2405–2409.

66. Saygin C, Roloff G, Hahn CN, et al. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv 2023;7:549–554.

67. Loschi M, Villy MC, Galimard JE, et al. Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies. Blood Adv 2025;9:6314–6325.

68. Berger G, van den Berg E, Sikkema-Raddatz B, et al. Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation. Leukemia 2017;31:520–522.

69. Kobayashi S, Kobayashi A, Osawa Y, et al. Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation. Leukemia 2017;31:1020–1022.

70. Williams LS, Williams KM, Gillis N, et al. Donor-derived malignancy and transplantation morbidity: risks of patient and donor genetics in allogeneic hematopoietic stem cell trans plantation. Transplant Cell Ther 2024;30:255–267.

71. Clark A, Thomas S, Hamblin A, et al. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT). Br J Haematol 2023;201:35–44.

72. Miao L, Wang X, Yao M, Tao Y, Han Y. Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis. Ann Hematol 2025;104:2581–2591.

73. Alkhateeb HB, Nanaa A, Viswanatha D, et al. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv 2022;6:528–532.

74. Bannon SA, Routbort MJ, Montalban-Bravo G, et al. Next- generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations. Front Oncol 2021;10:582213.

75. Bannon SA, DiNardo CD. Hereditary predispositions to myelodysplastic syndrome. Int J Mol Sci 2016;17:838.

76. Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood 2017;130:424–432.

77. Zhang MY, Keel SB, Walsh T, et al. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. Haematologica 2015;100:42–48.

78. Drazer MW, Kadri S, Sukhanova M, et al. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv 2018;2:146–150.

79. Holme H, Hossain U, Kirwan M, Walne A, Vulliamy T, Dokal I. Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. Br J Haematol 2012;158:242–248.

80. Huo L, Zhang Z, Zhou H, et al. Causative germline variant p.Y259C of DDX41 recurrently identified in acute lymphoblastic leukaemia. Br J Haematol 2023;202:199–203.

81. Arna AB, Patel H, Singh RS, et al. Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy. Front Oncol 2023;12:1087989.

82. Shinriki S, Matsui H. Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis. Front Oncol 2022;12:992340.

83. Zeng Y, Arisa O, Peer CJ, Fojo A, Figg WD. PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics. Semin Oncol 2024;51:19–24.